Peptides for Testosterone and Libido: A Practical Guide for Couples

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Low libido affects both partners in a relationship. For men: testosterone optimization and PT-141 address the hormonal and neurological components. For women: testosterone replacement, PT-141 (FDA-approved for HSDD), and GHK-Cu for vaginal health. Addressing both partners simultaneously produces the best outcomes.

The Couples Perspective on Sexual Health

Sexual dysfunction and low libido are rarely isolated individual problems — they affect both partners and the relationship as a whole. Addressing sexual health optimally requires considering both partners' hormonal status, psychological factors, and relationship dynamics. Peptide-based interventions can play an important role in restoring sexual vitality for both men and women.

For Men: Testosterone and PT-141

The foundation of male sexual health optimization is testosterone. Men with testosterone below 400–500 ng/dL commonly experience reduced libido, erectile dysfunction, and reduced sexual confidence. TRT, when indicated, consistently improves all aspects of male sexual function. PT-141 (1–2 mg subcutaneously 1–2 hours before sexual activity) addresses the neurological component of male sexual desire and arousal, and can be used as a complement to TRT or as a standalone intervention in men with normal testosterone but neurological sexual dysfunction.

For Women: Testosterone, PT-141, and Vaginal Health

Female sexual health involves multiple components: desire (primarily testosterone-dependent), arousal (both psychological and vascular), and comfort (dependent on vaginal health and estrogen levels). Testosterone replacement at physiological doses (typically 1–5 mg daily via cream or gel) improves libido in women, particularly postmenopausal women. PT-141 (1.75 mg subcutaneously 45 minutes before sexual activity) is FDA-approved for HSDD in premenopausal women and addresses the neurological component of female sexual desire. Vaginal estrogen (for postmenopausal women) addresses vaginal atrophy and discomfort that can impair sexual function.

Addressing Both Partners

The most effective approach to couples' sexual health involves: simultaneous evaluation and treatment of both partners' hormonal status, open communication about sexual needs and concerns, addressing psychological factors (stress, relationship dynamics, body image) alongside physiological interventions, and regular follow-up to adjust treatment as needed. Peptide-based interventions work best as part of a comprehensive approach that includes both physiological optimization and relationship support.